Quality-of-life assessment in advanced lung cancer: Considerations for evaluation in patients receiving chemotherapy

Richard J. Gralla, Nick Thatcher

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

There is increasing awareness of the need for accurate assessmentof quality of life in patients with lung cancer who are on clinical trials and in patient management. Self-reported multidimensional, validated, quality-of-life instruments assess physical, functional, psychological, social, and spiritual dimensions associated with lung cancer and its treatment. Such validated instruments are now available and are being utilized more frequently in clinical trials assessing the value of particular anticancer therapies. Such findings may influence the treatment of choice for patients with non-small-cell lung cancer (NSCLC), particularly in the advanced-disease setting where survival benefits from current treatments are modest, and the majority of patients present with three or more symptoms. Recently, a number of studies assessing quality of life in NSCLC have been published providing more insight into the effects of the disease and its treatment on the patient's perspective. Quality-of-life instruments that include patient reported outcomes ("PROS") and quality-of-life and symptom assessment are the only way to evaluate this crucial aspect of cancer care. As an example, Fossella and colleagues reported notable findings from the largest prospective evaluation (the TAX 326 trial) of quality of life using validated instruments in patients with NSCLC who received chemotherapy. Patients who received a docetaxel plus platinum combination regimen reported modest benefits in both quality of life and in disease-related parameters, such as pain control, weight loss, and performance status, compared to patients randomly assigned to the combination of vinorelbine and cisplatin. Compliance with the PRO assessment was high, supporting the feasibility of prospective quality-of-life evaluations in NSCLC. Important goals include building on these results by including quality-of-life assessment in all major clinical trials, and demonstrating feasible ways to incorporate this evaluation into daily clinical practice.

Original languageEnglish (US)
JournalLung Cancer
Volume46
Issue numberSUPPL. 2
DOIs
StatePublished - 2004
Externally publishedYes

Fingerprint

Lung Neoplasms
Quality of Life
Drug Therapy
Non-Small Cell Lung Carcinoma
Clinical Trials
docetaxel
Therapeutics
Symptom Assessment
Platinum
Cisplatin
Weight Loss
Psychology
Pain
Survival
Neoplasms

Keywords

  • Docetaxel
  • Non-small-cell lung cancer
  • Quality of life

ASJC Scopus subject areas

  • Oncology

Cite this

Quality-of-life assessment in advanced lung cancer : Considerations for evaluation in patients receiving chemotherapy. / Gralla, Richard J.; Thatcher, Nick.

In: Lung Cancer, Vol. 46, No. SUPPL. 2, 2004.

Research output: Contribution to journalArticle

@article{ced920cf46b74da5b06ebc785b7737bf,
title = "Quality-of-life assessment in advanced lung cancer: Considerations for evaluation in patients receiving chemotherapy",
abstract = "There is increasing awareness of the need for accurate assessmentof quality of life in patients with lung cancer who are on clinical trials and in patient management. Self-reported multidimensional, validated, quality-of-life instruments assess physical, functional, psychological, social, and spiritual dimensions associated with lung cancer and its treatment. Such validated instruments are now available and are being utilized more frequently in clinical trials assessing the value of particular anticancer therapies. Such findings may influence the treatment of choice for patients with non-small-cell lung cancer (NSCLC), particularly in the advanced-disease setting where survival benefits from current treatments are modest, and the majority of patients present with three or more symptoms. Recently, a number of studies assessing quality of life in NSCLC have been published providing more insight into the effects of the disease and its treatment on the patient's perspective. Quality-of-life instruments that include patient reported outcomes ({"}PROS{"}) and quality-of-life and symptom assessment are the only way to evaluate this crucial aspect of cancer care. As an example, Fossella and colleagues reported notable findings from the largest prospective evaluation (the TAX 326 trial) of quality of life using validated instruments in patients with NSCLC who received chemotherapy. Patients who received a docetaxel plus platinum combination regimen reported modest benefits in both quality of life and in disease-related parameters, such as pain control, weight loss, and performance status, compared to patients randomly assigned to the combination of vinorelbine and cisplatin. Compliance with the PRO assessment was high, supporting the feasibility of prospective quality-of-life evaluations in NSCLC. Important goals include building on these results by including quality-of-life assessment in all major clinical trials, and demonstrating feasible ways to incorporate this evaluation into daily clinical practice.",
keywords = "Docetaxel, Non-small-cell lung cancer, Quality of life",
author = "Gralla, {Richard J.} and Nick Thatcher",
year = "2004",
doi = "10.1016/S0169-5002(04)80040-0",
language = "English (US)",
volume = "46",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Quality-of-life assessment in advanced lung cancer

T2 - Considerations for evaluation in patients receiving chemotherapy

AU - Gralla, Richard J.

AU - Thatcher, Nick

PY - 2004

Y1 - 2004

N2 - There is increasing awareness of the need for accurate assessmentof quality of life in patients with lung cancer who are on clinical trials and in patient management. Self-reported multidimensional, validated, quality-of-life instruments assess physical, functional, psychological, social, and spiritual dimensions associated with lung cancer and its treatment. Such validated instruments are now available and are being utilized more frequently in clinical trials assessing the value of particular anticancer therapies. Such findings may influence the treatment of choice for patients with non-small-cell lung cancer (NSCLC), particularly in the advanced-disease setting where survival benefits from current treatments are modest, and the majority of patients present with three or more symptoms. Recently, a number of studies assessing quality of life in NSCLC have been published providing more insight into the effects of the disease and its treatment on the patient's perspective. Quality-of-life instruments that include patient reported outcomes ("PROS") and quality-of-life and symptom assessment are the only way to evaluate this crucial aspect of cancer care. As an example, Fossella and colleagues reported notable findings from the largest prospective evaluation (the TAX 326 trial) of quality of life using validated instruments in patients with NSCLC who received chemotherapy. Patients who received a docetaxel plus platinum combination regimen reported modest benefits in both quality of life and in disease-related parameters, such as pain control, weight loss, and performance status, compared to patients randomly assigned to the combination of vinorelbine and cisplatin. Compliance with the PRO assessment was high, supporting the feasibility of prospective quality-of-life evaluations in NSCLC. Important goals include building on these results by including quality-of-life assessment in all major clinical trials, and demonstrating feasible ways to incorporate this evaluation into daily clinical practice.

AB - There is increasing awareness of the need for accurate assessmentof quality of life in patients with lung cancer who are on clinical trials and in patient management. Self-reported multidimensional, validated, quality-of-life instruments assess physical, functional, psychological, social, and spiritual dimensions associated with lung cancer and its treatment. Such validated instruments are now available and are being utilized more frequently in clinical trials assessing the value of particular anticancer therapies. Such findings may influence the treatment of choice for patients with non-small-cell lung cancer (NSCLC), particularly in the advanced-disease setting where survival benefits from current treatments are modest, and the majority of patients present with three or more symptoms. Recently, a number of studies assessing quality of life in NSCLC have been published providing more insight into the effects of the disease and its treatment on the patient's perspective. Quality-of-life instruments that include patient reported outcomes ("PROS") and quality-of-life and symptom assessment are the only way to evaluate this crucial aspect of cancer care. As an example, Fossella and colleagues reported notable findings from the largest prospective evaluation (the TAX 326 trial) of quality of life using validated instruments in patients with NSCLC who received chemotherapy. Patients who received a docetaxel plus platinum combination regimen reported modest benefits in both quality of life and in disease-related parameters, such as pain control, weight loss, and performance status, compared to patients randomly assigned to the combination of vinorelbine and cisplatin. Compliance with the PRO assessment was high, supporting the feasibility of prospective quality-of-life evaluations in NSCLC. Important goals include building on these results by including quality-of-life assessment in all major clinical trials, and demonstrating feasible ways to incorporate this evaluation into daily clinical practice.

KW - Docetaxel

KW - Non-small-cell lung cancer

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=13244288025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13244288025&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(04)80040-0

DO - 10.1016/S0169-5002(04)80040-0

M3 - Article

C2 - 15698531

AN - SCOPUS:13244288025

VL - 46

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - SUPPL. 2

ER -